# Patient Capital Is the Missing Ingredient Deep-Tech Startups Can't Live Without

The conversation at IITMAA Sangam 2026 has crystallized around a harsh reality: patient capital deep-tech startups desperately need is vanishing from the ecosystem. Venture investors chasing quick returns have largely abandoned the sector, leaving founders of breakthrough technologies—from biotech to quantum computing—starved of the long-term funding required to move from lab to market. Multiple industry observers across India's startup landscape are now warning that without a fundamental shift in how we fund innovation, the nation risks losing its most ambitious technological ventures to better-capitalized competitors abroad.

Happenings

The IITMAA summit brought together founders, institutional investors, and policymakers to confront an uncomfortable truth: patient capital deep-tech startups require typically demands 7–12 years before meaningful returns materialize, yet most venture funds operate on 10-year lifecycles with pressure to show exits by year five or six.

Industry watchers highlighted that deep-tech ventures—those developing novel materials, advanced semiconductors, or biological therapeutics—require sustained R&D investment far exceeding traditional software startups. A typical deep-tech company burns through $2–5 million annually during development phases before reaching product-market fit, yet conventional VC rounds have compressed both check sizes and patience thresholds.

The summit emphasized that institutional investors, family offices, and government-backed funds are increasingly recognizing this gap. Several panelists noted that successful deep-tech ecosystems in the US and Europe rely on a deliberate mix of funding sources: government grants for early-stage research, corporate venture arms willing to wait for breakthroughs, and dedicated deep-tech funds with extended investment horizons.

India's startup funding landscape, by contrast, remains heavily weighted toward consumer tech and SaaS companies that can demonstrate revenue traction within 18–24 months. The absence of patient capital deep-tech startups need has already prompted some promising founders to relocate their operations to Silicon Valley or Singapore, where funding mechanisms are better suited to long development cycles.

Effects

The ripple effects of this capital shortage extend far beyond struggling startups. Entrepreneurs with genuinely transformative ideas—solutions to manufacturing inefficiencies, climate challenges, or healthcare delivery—are forced to either abandon projects or compromise on ambition by pivoting toward faster-monetizing applications that don't fully exploit their technology's potential.

For investors themselves, the short-term orientation creates a self-reinforcing trap. Without patient capital deep-tech startups can access, breakthrough innovations never reach commercialization, confirming the (false) belief that deep-tech is too risky. This perpetuates the cycle of underinvestment in precisely the areas where India could build genuine competitive advantage.

Ordinary citizens feel this indirectly but profoundly. Delayed medical breakthroughs, slower adoption of advanced manufacturing, and dependence on imported cutting-edge technology all trace back to insufficient domestic funding for deep innovation. The talent cost is equally real—young scientists and engineers, seeing limited funding pathways for ambitious projects, either leave the country or settle for incremental work.

Likely Viewpoints

The positions below are Trynews's AI-synthesized analysis of the likely sides of this debate — not quotes from named sources.

The debate over patient capital deep-tech startups need has split the investment community into two camps with fundamentally different risk appetites.

Supporters of dedicated patient capital mechanisms argue that the current venture model is structurally incompatible with deep-tech timelines. They point out that hardware, biotech, and climate solutions require 7–12 year development cycles before generating returns—a reality that terrifies fund managers answering to limited partners expecting exits within a decade. From this perspective, the solution isn't incremental tweaking but systemic change: government-backed venture funds, corporate venture arms with longer horizons, and family offices treating deep-tech as a generational wealth play. Advocates note that countries like Singapore and the UAE have already moved aggressively in this direction, creating dedicated deep-tech funds with patient capital structures. Without similar mechanisms in India, they warn, the country risks losing its most ambitious founders to overseas ecosystems.

Critics, however, raise a different concern: that patient capital alone won't solve the underlying problem of capital inefficiency in early-stage deep-tech. They argue that many startups fail not because of short-term pressure but because of poor market validation, weak unit economics, or technology that never achieves commercial viability. From this angle, flooding the market with patient capital could simply extend the runway of doomed ventures, masking fundamental flaws rather than solving them. These skeptics suggest the real bottleneck isn't money but mentorship—founders need experienced operators who've navigated deep-tech scaling, not just deeper pockets. They also question whether India's institutional framework can effectively steward patient capital vehicles without succumbing to political pressure or misallocation.

Both sides agree on one point: the status quo is unsustainable.

After Effects

The coming months will test whether rhetoric converts to action. Industry observers note that IITMAA has already signaled plans to convene a working group by Q2 2026 to draft a "patient capital framework" for Indian deep-tech—a blueprint that could influence government policy and institutional investor behavior. Watch for announcements around June-July 2026, when early proposals are expected to circulate among relevant ministries and venture stakeholders.

Meanwhile, several corporate venture arms and state-backed development banks have indicated preliminary interest in piloting patient capital vehicles. The National Investment and Infrastructure Fund (NIIF) is reportedly exploring a dedicated deep-tech allocation, with details potentially emerging by September 2026. If approved, this could unlock ₹500–1000 crore in committed capital within 18 months.

At the founder level, expect a bifurcation: startups with credible deep-tech credentials will likely see increased interest from patient capital sources, while those relying on traditional VC timelines will face tighter funding windows. Early indicators suggest a 15–20% shift in capital allocation toward longer-horizon vehicles by end of 2026.

The real test arrives in 2027–2028, when the first cohort of patient-capital-backed startups should begin demonstrating technical milestones and market traction. Success here could normalize the model; failure could trigger skepticism about whether patient capital is merely a subsidy for unfeasible ideas.

The Whole Picture

The IITMAA Sangam conversation reflects a maturing ecosystem recognizing its own constraints. Patient capital deep-tech startups need isn't a luxury—it's a structural necessity that India's venture landscape has neglected. The question now is execution: whether policymakers, institutional investors, and founders can align around frameworks that balance patience with accountability.

India's deep-tech ambitions—in semiconductors, biotech, quantum computing, and climate tech—won't materialize under the current venture model. Building patient capital deep-tech startups infrastructure requires coordination across government, institutions, and markets. The window to act is narrow. Countries moving faster will attract the talent and capital that India needs to remain competitive in technologies that will define the next decade.